Growth stock valuations are nearing post-Covid highs, with Moderna's market value surging by about a third amid concerns of a potential pandemic. Investors are speculating on Moderna's role in addressing the bird flu outbreak and potential future pandemics.
From @Breakingviews: Moderna’s market value has risen sharply since an outbreak of bird flu in cow herds in March. Investors are speculating Moderna is an obvious beneficiary should another pandemic strike. @rob_cyran explains why Wall Street is getting ahead of itself https://t.co/qc0dmM3fZE
Remember how HHS is working with Moderna on the new mRNA platform product for the bird flu? In the news… ”The recent rise of Moderna’s (MRNA.O), opens new tab stock tells a grim tale. The $56 billion company which pioneered a Covid vaccine has seen its market value rise 40%… https://t.co/iLdUPn1l7M
From @Breakingviews: Moderna’s valuation has risen by roughly a third amid growing concerns about another possible pandemic. @rob_cyran explains how investors might be getting ahead of themselves https://t.co/Nw7CGgd2t4
Growth stock valuations are approaching their post-Covid highs. via Morgan Stanley https://t.co/wyf7gS9kI8
Thanks Moderna. I'll keep that in mind. Moderna says next-generation COVID vaccine efficacy non-inferior to current shot https://t.co/spdrP18TNp